Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



 
Pertento Partners LLP
 
Signature:/s/ Eduardo Marques
Name/Title:Eduardo Marques, Managing Partner
Date:10/09/2026
 
Pertento Advisors LLC
 
Signature:/s/ Eduardo Marques
Name/Title:Eduardo Marques, Authorized Person
Date:10/09/2026
 
Eduardo Marques
 
Signature:/s/ Eduardo Marques
Name/Title:Eduardo Marques
Date:10/09/2026

Comments accompanying signature:  * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.
Exhibit Information

Exhibit A - Joint Filing Agreement

 

Exhibit A

JOINT FILING AGREEMENT

The undersigned agree that this Schedule 13G dated October 9, 2026 relating to the Ordinary Shares, par value of NIS 0.00001 per share, of Cellebrite DI Ltd. shall be filed on behalf of the undersigned.

  PERTENTO PARTNERS LLP
   
  By: /s/ Eduardo Marques
    Name: Eduardo Marques
    Title:   Managing Partner
   
   
  PERTENTO ADVISORS LLC
   
  By: /s/ Eduardo Marques
    Name: Eduardo Marques
    Title:   Authorized Person
   
  EDUARDO MARQUES
   
  By: /s/ Eduardo Marques